Method and compositions for administering taxanes orally to...

Details Method and compositions for administering taxanes orally to... Method and compositions for administering taxanes orally to...

2005-08-30

2005-08-30

Raymond, Richard L. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S449000

Reexamination Certificate

active

06936583

ABSTRACT:
Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.

REFERENCES:
patent: 5112817 (1992-05-01), Fukazawa et al.
patent: 5114951 (1992-05-01), King
patent: 5118493 (1992-06-01), Kelley et al.
patent: 5124330 (1992-06-01), King
patent: 5124338 (1992-06-01), King
patent: 5124339 (1992-06-01), King
patent: 5166207 (1992-11-01), Smith
patent: 5208238 (1993-05-01), King
patent: 5300282 (1994-04-01), King
patent: 5346897 (1994-09-01), King
patent: 5364843 (1994-11-01), King
patent: 5387685 (1995-02-01), Powell et al.
patent: 5395610 (1995-03-01), King
patent: 5405843 (1995-04-01), Fukazawa et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5416091 (1995-05-01), King
patent: 5438072 (1995-08-01), Bobee et al.
patent: 5439686 (1995-08-01), Desai et al.
patent: 5484809 (1996-01-01), Hostetler et al.
patent: 5525590 (1996-06-01), Bollinger et al.
patent: 5604237 (1997-02-01), Dumaitre et al.
patent: 5646176 (1997-07-01), Golik et al.
patent: 5665386 (1997-09-01), Benet et al.
patent: 5670536 (1997-09-01), Durr et al.
patent: 5750561 (1998-05-01), Bastart et al.
patent: 5756776 (1998-05-01), Bombardelli et al.
patent: 5776939 (1998-07-01), Kroin et al.
patent: 5968972 (1999-10-01), Broder et al.
patent: 5972992 (1999-10-01), Carver et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6096331 (2000-08-01), Desai et al.
patent: 6245805 (2001-06-01), Broder et al.
patent: 6395770 (2002-05-01), Broder et al.
patent: 6610735 (2003-08-01), Broder et al.
patent: 6730698 (2004-05-01), Broder et al.
patent: 413828 (1990-11-01), None
patent: 747385 (1996-12-01), None
patent: WO-92/12132 (1992-07-01), None
patent: WO-95/20980 (1995-08-01), None
patent: WO-97/27855 (1997-08-01), None
Baba et al., Cancer Chemother. Pharmacol. 36(5):361-67(1995).
Bal et al., Proc. of Am. Assoc. Pharm. Sci., Abstract PDD 7459 (Nov./1995).
Bartlett et al., J. Clin. Onc. 12(4):835-842 (1994).
Benel et al., J. Cont. Release 39:139-143 (1996).
Bissey, Euro J. Cancer 31A, Sup. 4:S1-S6 (1995).
Brock et al., Cancer Res. 55:459-462 (1995).
Chang et al., Clin. Pharm. Therap. 59:297-303 (1996).
Chiu et al., Proc. Of Am. Assoc. Pharm. Sci., Abstract PDD 7428 (Nov./1995).
Cresteil et al., Cancer Res. 54:386-392 (1994).
Duverne, et al., Antimicrobial Agents and Chemotherapy, 36(11):2462-2467 (1992).
Fisher et al., Proc. of ASCO, vol. 13:144 (1994), Abstract 369.
Fracasso et al., Proc. of ASCO 14: p. 486 (1995), Abstract 1585.
Germann et al., J. Bioenerg. Biomemb. 27:53-61 (1995).
Grant et al., Cancer Res. 54:357-361 (1994).
Harris et al., Cancer Research 54:4026/35 (1994).
Hunter, et al., Pharm Res. 10(5):743-749 (1993).
Jachez et al., J. Natl. Cancer Inst. 85(6):478-83 (1993).
Joel et al., Cancer Chemother. Pharmac. 37:125-133 (1995).
Keller, et al., Int. J. Cancer, 51:433-438 (1992).
Keogh et al., N.E. J. Med. 333(10):628-633 (1995).
Kloke et al., Klin. Wochenschr. 63:1081-1082 (1985).
Kobayashi, Proc. Ann. Meet. Am. Soc. Clin. Oncol. 15:A14889 (1996).
Kumar et al., J. of Pharmac. and Exp. Therapeutics. 268(3):1160-1165 (1994).
Lepage et al., Current Op. In Neph. And Hypert., 2:735-743 (1993).
Leu et al., Cancer Chem. Pharmac. 35(5):432-436 (1995).
Leveque et al., Anticancer Res. 15:331-336 (1995).
Loehrer, Seminars in Onc. 18(6):pp. 48-52 (1992).
Lum et al., Drug Resistance in Clin. Onc. and Hematology 9(2):319-336 (1995).
Lum et al., Clin. Onc. 10(10):1635-1642 (1992).
Montaseri et al., Pharm. Res. 12(9):S/429, Abstract PPDM 8411 (1995).
Muller, Proc. Nat. Acad. Sci. 91:13033-13037 (1994).
Pouvelle et al., J. Clin. Invest. 94:413-417 (1994).
Sato, et al., Cancer Chemother. Pharmacol. 35(4):271-277 (1995).
Scheffer et al., Nature Medicine 1(6):578-582 (1995).
Schinkel et al., J. Clin Invest. 96:1698-1705 (1995).
Schinkel et al., Cell, 77:491-502 (1994).
Slegsmund et al., J. Urol., 151:485-491 (1994).
Sikic et al., Anticancer Drug Resistance: Adv. Molec. Clin. Res., pp. 149-165 (1994).
Tsuruo, Jpn. J. Cancer Chemotherapy, 21(7):962:67, (1994) (English abstract only).
Terao, et al., J. Pharmacy & Pharmacol. 48:1083-1089(1996).
Vinceneux, et al., International Journal of Clinical Pharmacology, Therapy and Toxicology 24(3):153-158 (1986).
Wei, et al., Cancer, 15(3):161-163 (1996).
Wils et al., Biochem. Pharm. 48:1528-1530 (1994).

Affiliated with

Also associated with

Rating

Method and compositions for administering taxanes orally to... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and compositions for administering taxanes orally to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for administering taxanes orally to... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3444594